Anavex Life Sciences Cash Flow Statement 2009-2025 | AVXL

Net Income/Loss

$-43.002

$-47.505

$-47.978

$-37.909

$-26.281

$-26.295

$-17.253

$-13.46

$-14.737

$-12.108

Total Depreciation And Amortization - Cash Flow

$0.151

$0.007

$4.517

Other Non-Cash Items

$9.438

$17.215

$18.379

$8.231

$4.877

$6.315

$5.517

$4.06

$4.853

$2.127

Total Non-Cash Items

$9.438

$17.215

$18.379

$8.231

$4.877

$6.466

$5.517

$4.06

$4.86

$6.643

Change In Accounts Receivable

Change In Inventories

Change In Accounts Payable

Change In Assets/Liabilities

$-0.093

$0.658

$5.945

$-3.755

$-2.149

$0.031

$-1.147

$-0.172

$-0.135

$-0.073

Total Change In Assets/Liabilities

$2.752

$2.505

$5.361

$-0.706

$0.117

$1.302

$-0.847

$0.383

$0.64

$1.238

Cash Flow From Operating Activities

$-30.812

$-27.785

$-24.238

$-30.384

$-21.287

$-18.527

$-12.582

$-9.017

$-9.237

$-4.227

Net Change In Property, Plant, And Equipment

Net Change In Intangible Assets

Net Acquisitions/Divestitures

Net Change In Short-term Investments

Net Change In Long-Term Investments

Net Change In Investments - Total

Investing Activities - Other

Cash Flow From Investing Activities

Net Long-Term Debt

$-0.035

$-0.088

Net Current Debt

Debt Issuance/Retirement Net - Total

$-0.035

$-0.088

Net Common Equity Issued/Repurchased

$11.975

$29.651

$21.995

$158.794

$28.754

$17.832

$8.174

$27.271

$3.167

$12.344

Net Total Equity Issued/Repurchased

$11.975

$29.651

$21.995

$158.794

$28.754

$17.832

$8.174

$27.271

$3.167

$12.344

Total Common And Preferred Stock Dividends Paid

Financial Activities - Other

$-0.707

$-5.551

$-0.404

$-0.05

$-0.101

Cash Flow From Financial Activities

$11.975

$29.651

$21.288

$153.243

$28.35

$17.782

$8.073

$27.271

$3.133

$12.256

Net Cash Flow

$-18.837

$1.866

$-2.95

$122.859

$7.063

$-0.745

$-4.51

$18.253

$-6.104

$8.029

Stock-Based Compensation

$9.438

$16.37

$18.379

$8.231

$4.877

$6.431

$5.517

$4.136

$5.062

$1.634

Common Stock Dividends Paid